Aura Biosciences Inc (AURA) is not a strong buy at the moment for a beginner investor with a long-term focus. The lack of positive financial performance, insider selling, and absence of recent positive news or catalysts make it a less compelling investment opportunity despite hedge fund interest. Holding off for more favorable conditions or additional data is recommended.

Technical Analysis

The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 70.495, and moving averages are converging, showing no strong directional trend. The stock is trading near its R1 resistance level of 5.97, with key support at 5.5.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds are significantly increasing their buying activity, with a 593.96% increase over the last quarter.

Neutral/Negative Catalysts

Insiders are selling heavily, with a 487.89% increase in selling activity over the last month. The company has no recent news or event-driven catalysts. Financial performance shows no revenue growth, and EPS has declined YoY.

Financial Performance

In Q3 2025, revenue remained at 0 with no YoY growth. Net income improved by 24.18% YoY but remains negative at -$26.13 million. EPS dropped by 4.76% YoY to -0.4, and gross margin stayed at 0.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst rating or price target changes.

4 Analyst Rating

Wall Street analysts forecast AURA stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.890

Low

Averages

19.33

High

Current: 5.890

Low

Averages

19.33

High

Evercore ISI

Outperform

initiated

$13

AI Analysis

2025-11-25

Reason

Evercore ISI

Price Target

$13

AI Analysis

2025-11-25

initiated

Outperform

Reason

Evercore ISI re-initiated coverage of Aura Biosciences with an Outperform rating and $13 price target. Aura uses a photosensitive payload to kill tumor cells in a handful of "underserved," early-stage indications and early data has been "quite supportive," the analyst tells investors. The company's main target populations are earlier than the market is used to considering and with a safe and easy-to-give regimen, Aura could potentially open up these indications and avoid competition, the analyst added.

H.C. Wainwright

Andres Maldonado

initiated

$22

2025-05-28

Reason

H.C. Wainwright

Andres Maldonado

Price Target

$22

2025-05-28

initiated

Reason

H.C. Wainwright analyst Andres Maldonado assumed coverage of Aura Biosciences with a Buy rating and $22 price target. Aura is advancing a tumor-targeted platform that combines localized cytotoxicity with systemic immune activation, anchored by its proprietary virus-like drug conjugate technology, the analyst tells investors in a research note. The firm says the company is positioned to redefine the treatment paradigm in ocular oncology, where early intervention is often avoided due to the destructive nature of existing therapies.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AURA

Unlock Now

AURA Should I Buy

AURA Should I Buy

Should You Buy Aura Biosciences Inc (AURA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch